[Influence on atherosclerosis of improvement of bone mineral density after medication for osteoporosis].
Yamada
Shinsuke
S
Department of Metabolism, Endocrinology and Molecular Medicine, Osaka City University Graduate School of Medicine.
Inaba
Masaaki
M
Nishizawa
Yoshiki
Y
D019386:Alendronate / Q000494:pharmacology / Q000627:therapeutic use*; D016632:Apolipoprotein A-I / Q000378:metabolism; D001172:Arthritis, Rheumatoid / Q000150:complications / Q000378:metabolism; D050197:Atherosclerosis / Q000209:etiology* / Q000517:prevention & control*; D015519:Bone Density; D050071:Bone Density Conservation Agents / Q000494:pharmacology / Q000627:therapeutic use*; D001842:Bone and Bones / Q000378:metabolism*; D008076:Cholesterol, HDL / Q000378:metabolism; D006801:Humans; D008798:Mevalonic Acid / Q000378:metabolism; D010024:Osteoporosis / Q000150:complications / Q000188:drug therapy* / Q000378:metabolism*
D016632:Apolipoprotein A-I; D050071:Bone Density Conservation Agents; D008076:Cholesterol, HDL; D008798:Mevalonic Acid; D019386:Alendronate